Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

Journal of the American College of Cardiology

Volumn 44, Issue 2, 2004, Pages 362-368

  Schieffer, Bernhard ^a,c   Bünte, Christoph ^a   Witte, Jana ^a   Hoeper, Kirsten ^a   Böger, Rainer H ^b   Schwedhelm, Edzard ^b   Drexler, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Carl Neuberg Str 1 ^*  (Germany)

Author keywords

ACE; ANG II; angiotensin II; angiotensin II type 1 receptor; angiotensin converting enzyme; AT1; blood pressure; BP; CAD; coronary artery disease; COX; cyclooxygenase; ENAL; enalapril; EUROPA

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 6; PROSTAGLANDIN E2; THROMBOXANE A2;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATTENUATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; DINOPROSTONE; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLATELET AGGREGATION; TETRAZOLES; THROMBOXANE A2;

EID: 3242720779     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.03.065     Document Type: Article

References (42)

1. Ross R. Atherosclerosis is an inflammatory disease. N Engl J Med. 340:1999;115-126
2. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 99:1999;855-860
3. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 19:1999;2847-2853
4. Mallat Z., Besnard S., Duriez M., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res. 85:1999;E17-E24
5. de Vries J.E. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med. 27:1995;537-541
6. Wang P., Wu P., Siegel M.I., et al. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem. 270:1995;9558-9563
7. Jungi T.W., Brcic M., Eperon S., et al. Transforming growth factor-beta and interleukin-10, but not interleukin-4, down-regulate procoagulant activity and tissue factor expression in human monocyte-derived macrophages. Thromb Res. 76:1994;463-474
8. Berg D.J., Zhang J., Lauricella D.M., et al. Il-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J Immunol. 166:2001;2674-2680
9. Lacraz S., Nicod L.P., Chicheportiche R., et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 96:1995;2304-2310
10. Mostafa Mtairag E., Chollet-Martin S., Oudghiri M., et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res. 49:2001;882-890
11. Von Der Thusen J.H., Kuiper J., Fekkes M.L., et al. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J. 15:2001;2730-2732
12. Smith D.A., Irving S.D., Sheldon J., et al. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 104:2001;746-749
13. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850
14. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 342:2000;145-153
15. Fox K.M. for the EURopean trial. On reduction of cardiac events with Perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 362:2003;782-788
16. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques Potential implications for inflammation and plaque instability. Circulation. 101:2000;1372-1378
17. Biassuci L., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 94:1996;874-877
18. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 105:2002;1650-1655
19. Vane J.R., Botting R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 47:(Suppl 2):1998;S78-S87
20. FitzGerald G.A., Pedersen A.K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 67:1983;1174-1177
21. Strawn W.B., Chappell M.C., Dean R.H., et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 101:2000;1586-1593
22. Kraemer C., Sunkomat J., Witte J., et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan Role of the active metabolite EXP3179. Circ Res. 90:2002;770-776
23. 2 in a murine model of inflammation Possible role of cyclooxygenase-2. Proc Natl Acad Sci USA. 93:1996;4885-4890
24. Hamberg M., Samuelsson B. On the metabolism of prostaglandins E1 and E2 in man. J Biol Chem. 246:1971;6713-6721
25. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem. 47:2001;418-425
26. Fitzpatrick F.A., Aguirre R., Pike J.E., et al. The stability of 13,14-dihydro-15-keto-PGE2. Prostaglandins. 19:1980;917-922
27. Rossi E., Biasucci L.M., Citterio F., et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease Predictive role of C-reactive protein. Circulation. 105:2002;800-803
28. Heinrich P.C., Behrmann I., Muller-Newen G., et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 334:1998;297-314
29. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:1994;2493-2503
30. Alderman M.H., Madhavan S., Ooi W.L., et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 324:1991;1098-1104
31. Diet F., Pratt R.E., Berry G.J., et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 94:1996;2756-2767
32. Hoshida S., Kato J., Nishino M., et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation. 6;103:2001;630-633
33. Schieffer B., Luchtefeld M., Braun S., et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 87:2000;1195-1201
34. Gurjar M.V., Sharma R.V., Bhalla R.C. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol. 19:1999;2871-2877
35. Fitzgerald D.J., Roy L., Catella F., et al. Platelet activation in unstable coronary disease. N Engl J Med. 315:1986;983-989
36. Patrono C., Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol. 80:1997;17E-20E
37. Schieffer B., Schmidt B. AT1-receptor antagonists Metabolism and potential implication. J Med Chem. 46:2003;2261-2270
38. Bauriedel G., Skowasch D., Schneider M., Andrie R., Jabs A., Luderitz B. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel A pilot study with whole-blood aggregometry. Am Heart J. 145:2003;343-348
39. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 99:1999;855-860
40. Khan B.V., Navalkar S., Khan Q.A., Rahman S.T., Parthasarathy S.J. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. Am Coll Cardiol. 15;38:2001;1662-1667
41. Navalkar S., Parthasarathy S., Santanam N., Khan B.V. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol. 37:2001;440-444
42. Kovanen P.T., Lindstedt M.K., Shiota N., Kokkonen J.O. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation. 25;102:2000;E32